| Document |
Document Title |
|
WO/2004/022552A1 |
A compound of the following structure: wherein R1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom; R2 is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbRc, CH2ORd, or C...
|
|
WO/2004/022523A2 |
The present invention relates to compounds of formula (AA), (I) and (X), useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment ...
|
|
WO/2004/018414A2 |
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X=NH Y=CO, CS, -C(=N-CN) or X and Y together form an alkene, or C3-C5 cycloalkyl; R1 is -COOH; R2 is an electron withdrawing g...
|
|
WO/2004/016213A2 |
The present invention relates to solid phase or solution phase combinatorial libraries of autoinducer analogs. The present invention also relates to autoinducer agonists and antagonists. In addition, the present invention relates to meth...
|
|
WO/2004/013085A1 |
Compounds having the formula are useful for treating conditions which arise from or are exacerbated by angiogenesis. Also disclosed are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, metho...
|
|
WO/2004/013118A1 |
Azulene derivatives represented by the following general formula (I) and salts thereof are useful as Na+-glucose cotransporter inhibitors in, for example, remedies for diabetes, etc., in particular, insulin-independent diabetes (type 2 d...
|
|
WO/2004/011410A1 |
Compounds of formula (I):wherein variable groups are as defined within; for use in the inhibition of 11$g(b)HSD1 are described.
|
|
WO/2004/009079A1 |
A substantially purified compound of the formula: a composition comprising a therapeutically effective amount of at least one compound of the formula, alone or in combination with at least one additional therapeutic agent, and methods of...
|
|
WO/2004/009749A1 |
2,4,5-trialkyl-substituted 3,6-dihydro-2H-pyrans that are useful as fragrance ingredients, particularly in fine fragrances and functional perfumery.
|
|
WO/2004/009067A1 |
The invention relates to metabolites of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine as free bases and/or in the form of physiologically acceptable salts, corresponding medicaments, the use of [2-(3-methoxyphenyl)-cyclohexylmethy...
|
|
WO/2004/009574A1 |
The invention relates to a process for preparing discodermolide, for preparing intermediates for the manufacture of discodermolide and discodermolide analogues and to the intermediates obtained during the process. Wherein the process pro...
|
|
WO/2004/009573A1 |
The present invention relates compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R15 and R16 represent a variety of substituents; and pharmaceutically acceptable salts thereof. The compounds are of particular use in th...
|
|
WO/2004/006865A2 |
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.
|
|
WO/2004/005478A2 |
This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA cons...
|
|
WO/2004/005275A1 |
The present invention provides a novel method for producing compound of formula (I), its acid form or any salt form, where R¿1? is H or CH¿3?, by solid state fermentation using fed-batch technique by culturing microorganisms capable of...
|
|
WO/2004/002979A2 |
The invention relates to chiral 3,4-dihydro-2H-pyran compounds, to diastereomers thereof, and to the use of these compounds as chiral dopants for liquid crystal systems. The invention also relates to non-polymerizable or polymerizable li...
|
|
WO/2004/000827A1 |
The invention relates to a method for producing carbonyl compounds. The inventive method is based on the reaction of liquid-phase oxidation of unsaturated heterocyclic compounds and the derivatives thereof including a link in C=C cycle i...
|
|
WO/2004/000825A1 |
The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are dise...
|
|
WO/2004/000783A1 |
The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia. This invention further relates to co...
|
|
WO/2004/000771A1 |
The invention relates to 3,3,4,4-tetrafluorocyclopentane compounds of formula (I), in which R1, A1, A2, Z1, Z2 and m are defined as cited in claim 1. Said compounds are suitable for use as components of liquid crystal media.
|
|
WO/2004/000811A1 |
This invention is directed generally to hydroxamic acid and amide compounds (including salts of such compounds), and, more particularly, to aryl- and heteroaryl-arylsulfonylmethyl hydroxamic acids and amides that, inter alia, inhibit p...
|
|
WO2003048148A9 |
The present invention relates to compounds with structures resembling natural statins isolated from Penicillium sp. (Formula I); where R1 represents OH, C6H5COO, R6COO and R6 represents C1-C5 alkyl; R2-4 represents H, C1-C5 alkyl, C1-C5 ...
|
|
WO/2003/105769A2 |
The invention is directed to compounds of formula (I) wherein X is O, OR NH; R’ is a hydrocarbon chain; R3 and R4 are hydrogen, OH or a monosaccharide; R5 is hydrogen or a monosaccharide; Q’ is optionally present and may be a C1-10 h...
|
|
WO/2003/104215A1 |
A process for producing tetrahydropyran-4-ol, characterized by comprising: a cyclization step in which 3-buten-1-ol, a formaldehyde compound, and formic acid are reacted to form tetrahydropyranyl 4-formate, which is represented by the fo...
|
|
WO/2003/103656A1 |
Drugs having inhibitory activity against NF-κB activation, containing as the active ingredient substances selected from the group consisting of compounds represented by the general formula (I), pharmacologically acceptable salts thereof...
|
|
WO/2003/101382A2 |
This invention relates to compounds of formula (I), and a method for treating anthrax or inhibiting lethal factor by administrating a composition containing a compound of formula (I) and a pharmaceutically acceptable carrier. This invent...
|
|
WO/2003/099836A1 |
An SGLT2 inhibiting compound is provided having the formula[Chemical structure] A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with ...
|
|
WO/2003/099769A1 |
The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically ...
|
|
WO/2003/099008A1 |
Pests can be controlled by applying an effective amount of a compound of formula (1):wherein R is C2-C6 alkyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)C1-C2 alkyl, 3,3,3-trifluoropropyl or 3,3,3-trifluoro-2-methylpropyl to pests or habitats ...
|
|
WO2003074508B1 |
The present invention relates to compounds and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having anti-proliferative activities, as well as methods for treating various diseases associated w...
|
|
WO/2003/097575A2 |
The invention provides novel amino-functionalised chalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infecti...
|
|
WO/2003/097576A2 |
The invention provides novel diamino-functionalised chalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infec...
|
|
WO/2003/097574A2 |
The invention provides novel alkoxyaminochalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is al...
|
|
WO/2003/097627A1 |
A method of forming an iron hydroxypyrone compound comprising reacting an iron salt of a carboxylic acid and a hydroxypyrone in an aqueous solution at a pH greater than 7.
|
|
WO2003014102B1 |
The present invention relates to certain substituted polyketides of formula (I), wherein A, B, C, D, E, F and m are as defined herein, pharmaceutical compositions containing said compounds, and the use of said compounds in treating tumors.
|
|
WO/2003/095421A1 |
In the present specification we describe a new class of compounds, designed to modulate the ability of blood vessels to synthesize NO from L-arginine. In particular we have identified novel compounds which enhance the entry of L-arginine...
|
|
WO/2003/095441A1 |
Compounds of formula (I) are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.
|
|
WO/2003/092670A1 |
Compounds of formula (I): and their salts, solvates, prodrugs, etc., wherein teh substituents have the values mentioned herein, are bombesin antagonists, which have utility in variety of therapeutic areas including male and female sexual...
|
|
WO/2003/093286A1 |
Methods are described for the preparation of combinatorial libraries of potentially biologically active disaccharide compounds. These compounds are variously functionalized, with a view to varying lipid solubility size, function and othe...
|
|
WO/2003/093208A1 |
A homogenous process for the hydrogenation of the carboxylic acids and/or derivatives thereof in the presence of a catalyst comprising ruthenium, rhodium, iron, osmium or palladium, and an organic phosphine is described in which the hydr...
|
|
WO/2003/091189A1 |
Compounds of the formula: wherein R, R1 and R4 are defined in the specification, and pharmaceutically acceptable salts, esters and tautomers thereof, having activity at peripheral cannabinoid receptors, commonly designated the CB2 recept...
|
|
WO/2003/091202A1 |
Diketohydrazine derivatives represented by the following general formula (I) (wherein each symbol is as defined in the description) and pharmaceutically acceptable salts thereof: (I) Because of having a cysteine protease inhibitory activ...
|
|
WO/2003/091247A2 |
This invention is directed generally to proteinase (also known as 'protease') inhibitors, and more particularly, to piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids that inter alia, inhibit matrix metalloproteinase (also known...
|
|
WO/2003/089396A1 |
Nonmetallic, chiral organic catalysts are used to catalyze an enantioselective aldol coupling reaction between aldehyde substrates. The reaction may be carried out with a single enolizable aldehyde, resulting in dimerization to give a β...
|
|
WO/2003/087387A1 |
The present invention relates to a process for the synthesis of optically enriched dextro- and leavo-rotatory isomers of rose oxide from racemic citronellol.
|
|
WO/2003/087040A2 |
The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyshpidemias, dysproteinemias, and glucose metabolism disorders comp...
|
|
WO/2003/087108A2 |
The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders com...
|
|
WO/2003/084512A1 |
A method of producing a processed kava product involves using an extraction solvent, such as liquid CO2 to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parameter...
|
|
WO/2003/084911A1 |
The present invention provides a process for selectively converting dihydroxy-or-polyhydroxy alcohols into carbonyl compounds using dioxygen (O2) as oxidant in the presence of a catalytic system comprising (1) a copper salt, a copper sal...
|
|
WO/2003/084558A1 |
A method of producing a processed kava product involves using an extraction solvent, such as liquid CO¿2? to preferentially extract different kavalactones from the source material at different rates. By controlling the extraction parame...
|
